Abstract
Intratumoral heterogeneity and genetic instability within gliomas may allow intrinsically immunoresistant (IR) cells to escape alloreactive cytotoxic T lymphocyte (aCTL) cellular immunotherapy. The potential existence of aCTL-resistant variants prompted us to investigate whether cellular immunotherapy resistant glioma models could be isolated. To generate the models, repeated intermittent or continuous selective pressure (ISP or CSP) with multiple aCTL populations was applied to a low-passage glioblastoma cell explant, 13-06-MG, obtained from a patient at initial diagnosis. IL-6 and IL-8 secretion was greater in coincubates of aCTL cells with 13-06-ISP and 13-06-CSP immunoselected cells than those with 13-06-MG parental cells. Initially, the immunoselected cells were less sensitive to aCTL lysis; however, the reduced aCTL-sensitivity was not maintained upon further selection. We therefore isolated IR clones from continuously immunoselected cells (13-06-CSP). The frequency of IR clones was 1-6 cells per 10,000 immunoselected cells. Two clones selected for further study, 13-06-IR29 and 13-06-IR30, resisted aCTL lysis in the absence of immunoselective pressure. Cytogenetic analyses revealed structural anomalies and genomic imbalan...Continue Reading
References
May 1, 1991·Cancer Genetics and Cytogenetics·J R SawyerG J Roloson
May 15, 1989·International Journal of Cancer. Journal International Du Cancer·L RivoltiniG Parmiani
Jan 1, 1980·Journal of Immunological Methods·J J HesslingN L Levy
Mar 1, 1995·In Vitro Cellular & Developmental Biology. Animal·R A GjersetH Lin
Jun 1, 1995·Gynecologic Oncology·A J PapadopoulosK S Raju
Jul 15, 1993·Cancer·C N BaxevanisM Papamichail
Dec 9, 1997·Cancer Immunology, Immunotherapy : CII·C A KruseK O Lillehei
Jul 14, 1998·In Vitro Cellular & Developmental Biology. Animal·C A KruseB C Liang
Sep 15, 1999·Journal of Immunological Methods·R T Carson, D A Vignali
Oct 6, 1999·The Journal of Experimental Medicine·J P MedemaR Offringa
Feb 7, 2001·Cancer Immunology, Immunotherapy : CII·C L SlingluffV H Engelhard
Sep 20, 2001·Proceedings of the National Academy of Sciences of the United States of America·J P MedemaR Offringa
Jan 5, 2002·Hematology/oncology Clinics of North America·N Virasch, C A Kruse
Mar 20, 2002·Current Neurology and Neuroscience Reports·D B Paul, C A Kruse
Aug 1, 2002·Oncogene·Emilio FioreIvan Stamenkovic
Aug 13, 2003·The Biochemical Journal·Pachiyappan KamarajanChuck C-K Chao
Sep 16, 2003·Journal of Immunotherapy·Steven A RosenbergMark E Dudley
Oct 1, 2003·The Prostate·Adrie van BokhovenMarileila Varella-Garcia
Mar 18, 2004·Cancer Research·Akihide FujimotoDave S B Hoon
May 12, 2004·Neuro-oncology·German G GomezCarol A Kruse
Sep 25, 2004·Cell Death and Differentiation·R Hofer-WarbinekR de Martin
Apr 16, 2005·Neuro-oncology·Daniel J BratErwin G Van Meir
Citations
Sep 8, 2007·Cancer Immunology, Immunotherapy : CII·Natalie KronikZvia Agur
Apr 7, 2007·Journal of Immunotherapy·German G Gomez, Carol A Kruse
Sep 4, 2015·Neuro-oncology·Richard G EversonRobert M Prins
Mar 5, 2014·Targeted Oncology·Laurent-Olivier RoyDavid Fortin
Jun 3, 2016·BMC Neuroscience·Ilan VolovitzZvi Ram